Lung cancer is the most frequent cause of cancer-related deaths worldwide. Every year, 1· 8
million people are diagnosed with lung cancer, and 1· 6 million people die as a result of the …

Targeted therapies are substantially changing the management of lung cancers. These
treatments include drugs that target driver mutations, those that target presumed important …

Introduction The standard chemotherapy for squamous NSCLC (sqNSCLC) includes
platinum plus gemcitabine. Sintilimab, an anti–programmed cell death protein 1 antibody …

Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with
activating EGFR mutation-positive non-small-cell lung cancer (NSCLC), median progression …

Purpose To provide evidence-based recommendations to update the American Society of
Clinical Oncology guideline on systemic therapy for stage IV non–small-cell lung cancer …

Purpose: Blood-based circulating-free (cf) tumor DNA may be an alternative to tissue-based
EGFR mutation testing in NSCLC. This exploratory analysis compares matched tumor and …

Background Epidermal growth factor receptor (EGFR) mutation positive (M+) non‐small cell
lung cancer (NSCLC) is an important subtype of lung cancer comprising 10% to 15% of non …

In the past decade, the characterization of non-small-cell lung cancer (NSCLC) into
subtypes based on genotype and histology has resulted in dramatic improvements in …

Importance Continuing molecularly targeted treatment beyond disease progression in non–
small-cell lung cancer (NSCLC) has appeared promising in retrospective analyses …

Purpose: We established a CT-derived approach to achieve accurate progression-free
survival (PFS) prediction to EGFR tyrosine kinase inhibitors (TKI) therapy in multicenter …